Results from the AIRFLOW-1 study demonstrate that targeted lung denervation did not produce any severe adverse reactions in patients with chronic obstructive pulmonary disease (COPD) after 3 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results